Press information package – ILSI Biomed/Gvahim panel session at Biomed 2009 congress

The panel members from the Biotech Industry and Biotech HR Companies discussed outcomes of a survey to Biotech / Biopharma CEO as well as current and expected recruitment trends in Biotech and place of new immigrants (Olim) in Life Science Industry.
By:
 
June 22, 2009 - PRLog -- Press information package – ILSI Biomed/Gvahim panel session at Biomed 2009 congress
Wednesday 17 June, Hall B, Hotel David Intercontinental

The current global crisis is deeply affecting the biotech / biopharma and medical devices in many ways. However, even in such a difficult environment, for those with good ideas and strong background, difficult times also open opportunities. As raised by Steve Rhodes, CEO of Misgav Venture Accelerator, the most adventurous scientists will find opportunities in an incubator: it is the right time to bring new projects to incubators, leverage money available at Chief Scientist Office or Private Investors. He is advising to entrepreneurs to create now companies that will be of interest for Venture Capital when the biotech world will exit the global crisis.

Pinhas Avda, General Manager of Pharma-Job presented an overview of the job market for the Healthcare and Life Science Industry: like the whole market, the Pharma industry, the biotech and medical devices have been affected by the global recession. This effect varies according to the segments of this bio industry: overall reduction of salaries between 10 to 50%, smaller mobility - less people are leaving their jobs or taking risks to move. This phenomenon is very much observed among senior managers. People that left their jobs before the start of this global crisis are now finding it harder to find another employment. A significant reduction is observed in hiring of R&D, Chemistry and Medical Device workers is observed, in particular for senior managers’ positions.

Ayala Kaplan, Manager of the Biotech Department at Ethosia HR sees many opportunities for new immigrants with high educational background, in the biopharma and medical devices area in comparison to other high-tech industries. This Life Science companies R&D field is characterized by strong requirements for high education where immigrants have already a suitable background, thus, have a relative advantage. Biotech and Medical Devices companies usually do not have human resources managers. Therefore, being connected to management is important. This could be a disadvantage for new immigrants without relevant connections when trying to reach these jobs. Finally, an Ethosia survey shows a relative stability of Pharma companies’ salaries. This could be a reason why many people try to join Pharmaceutical companies where salaries are perceived high vs. biotech.

Alain Zeitoun, Board Member of Gvahim and Biotech/Devices Professional presented the results of Gvahim survey in collaboration with Israel Life Science Industry. This survey was sent to 787 companies of ILSI database, 7% answered (n=55) with high percentage of small companies (up to 30 people), a large majority in the Medical Device field. When asked which profiles they might recruit late 2009 or mid 2010 if financial situation allows, a majority answered R&D, Clinical /Preclinical (58% and 42%) followed by Marketing/Sales/Account Management, Business Development (42% and 27%). Interestingly, 86% of these CEO would strongly consider recruiting Olims but would require either a previous experience in a similar company abroad and/or a strong international network in their field.

Gvahim (http://www.gvahim.org.il) aims to support talented professionals making Aliyah. For the past ten years, a growing number of them have decided to make Aliyah and succeed professionally in Israel. Since its launching in March 2006, Gvahim has offered different types of services designed to promote their professional success in Israel: individual support, professional workshops and networking through its networks. Gvahim is a joint initiative of the Rashi Foundation and Israeli business leaders, all volunteers.
About Alain Zeitoun – with a double competence Medical Doctor + MBA degrees, Alain made Aliyah in 1998 to join the Israeli subsidiary of the American Pharma company Merck/MSD. After senior business positions in Israel and a European Marketing position, his “natural development” career was to move back abroad for a corporate senior position. However, as an Oleh, he decided to focus his career in Israel. Choosing a career in Israel drove him to enter the world of biotechnologies and medical devices. Alain has been one of the founders of Gvahim in 2006, has trained new immigrants in the project to develop their network and is coaching many Olim in Healthcare.

Misgav (http://www.misgav-venture.com) was founded in 1992. It is a member of The Trendlines Group, a leading Israeli business development and marketing consulting firm, making it the only Israeli incubator owned by a business development firm. Portfolio companies receive support from the Trendlines Israel Fund and the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor.

# # #

Gvahim provides a variety of unique solutions in the areas of business and career development to the international community in Israel, and brings together the top leaders of the Israeli economy and the global leaders of tomorrow.
End



Like PRLog?
9K2K1K
Click to Share